Keywords: blow, genentech, xoma, drug, fails, ra, partner

Blow for Genentech and Xoma as drug fails in RA

Article | 19 May 2003

Print This

Genentech and partner Xoma have been forced to abandon Phase II trials of Raptiva (efalizumab) in patients with moderate-to-severe rheumatoid ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in